Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 12, 2023 08:00 ET
|
Mustang Bio, Inc.
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months ...
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
May 18, 2023 08:03 ET
|
Mustang Bio, Inc.
uBriGene (Boston) Biosciences to acquire Mustang Bio’s Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support...
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 12, 2023 16:05 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
May 11, 2023 16:03 ET
|
Mustang Bio, Inc.
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May ...
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 29, 2023 16:15 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
January 17, 2023 08:15 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
December 19, 2022 08:30 ET
|
Mustang Bio, Inc.
MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE...
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 14, 2022 16:05 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments
January 26, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...